Retro Bio going for an autophagy enhancer seems sensible to me. Whether stimulating SOX2 could go too far is, however, a question that only experimentation will answer.
If a company like LLY has moderate success that still means thereâs not a conversation or endpoint of immortality, i.e LEV. Iâm not complaining, but it might be better to be upfront about it now rather than have a focus group message of âextending healthy lifespan by 10 yearsâ when investors and others likely are expecting more than that. Itâs the elephant in the room, but it also might be more effective if LEV is the goal.